tiprankstipranks
Advertisement
Advertisement

ANRO Stock Latest News

Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
The FlyAlto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
3d ago
ANRO
Alto Neuroscience files to sell 6M shares of common stock for holders
PremiumThe Fly
Alto Neuroscience files to sell 6M shares of common stock for holders
14d ago
ANRO
Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright
PremiumThe Fly
Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright
22d ago
ANRO
Alto Neuroscience price target lowered to $21 from $22 at Wedbush
PremiumThe Fly
Alto Neuroscience price target lowered to $21 from $22 at Wedbush
22d ago
ANRO
Morning Movers: Immunovant sinks after batoclimab trials miss goal
PremiumThe Fly
Morning Movers: Immunovant sinks after batoclimab trials miss goal
22d ago
BP
ALK
Alto Neuroscience price target lowered to $38 from $41 at Baird
PremiumThe FlyAlto Neuroscience price target lowered to $38 from $41 at Baird
22d ago
ANRO
Alto Neuroscience price target lowered to $44 from $49 at JonesResearch
Premium
The Fly
Alto Neuroscience price target lowered to $44 from $49 at JonesResearch
22d ago
ANRO
Closing Bell Movers: Globalstar spikes on acquisition report
Premium
The Fly
Closing Bell Movers: Globalstar spikes on acquisition report
22d ago
FC
AMZN
Alto Shifts Focus to ALTO-207 After ALTO-101 Data
PremiumCompany Announcements
Alto Shifts Focus to ALTO-207 After ALTO-101 Data
22d ago
8K
ANRO
Pipeline Strength and Key Late-Stage Assets Drive Upside in Alto Neuroscience Despite ALTO-101 Setback
PremiumRatings
Pipeline Strength and Key Late-Stage Assets Drive Upside in Alto Neuroscience Despite ALTO-101 Setback
22d ago
ANRO
Alto Neuroscience announces ALTO-101 did not achieve statistical significance
PremiumThe Fly
Alto Neuroscience announces ALTO-101 did not achieve statistical significance
22d ago
ANRO
Alto Neuroscience price target raised to $41 from $22 at Baird
PremiumThe Fly
Alto Neuroscience price target raised to $41 from $22 at Baird
1M ago
ANRO
Alto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile
PremiumRatingsAlto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile
1M ago
ANRO
Alto Neuroscience price target raised to $22 from $13 at Wedbush
Premium
The Fly
Alto Neuroscience price target raised to $22 from $13 at Wedbush
1M ago
ANRO
Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating
Premium
Ratings
Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating
1M ago
ANRO
Alto Neuroscience Secures $120 Million Private Placement Financing
PremiumCompany Announcements
Alto Neuroscience Secures $120 Million Private Placement Financing
1M ago
8K
ANRO
Alto Neuroscience to sell 2.9M shares at $20.00 in private placement
PremiumThe Fly
Alto Neuroscience to sell 2.9M shares at $20.00 in private placement
1M ago
ANRO
Alto Neuroscience reports FY25 EPS ($2.19) vs. ($2.50) last year
PremiumThe Fly
Alto Neuroscience reports FY25 EPS ($2.19) vs. ($2.50) last year
1M ago
ANRO
Alto Neuroscience sees cash runway into 2028
PremiumThe Fly
Alto Neuroscience sees cash runway into 2028
1M ago
ANRO
Alto Neuroscience price target raised to $28 from $27 at BTIG
PremiumThe FlyAlto Neuroscience price target raised to $28 from $27 at BTIG
2M ago
ANRO
Alto Neuroscience completes patient enrollment in ALTO-101 trial
Premium
The Fly
Alto Neuroscience completes patient enrollment in ALTO-101 trial
2M ago
ANRO
Alto Neuroscience issued patent for ALTO-207
Premium
The Fly
Alto Neuroscience issued patent for ALTO-207
3M ago
ANRO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >